157 related articles for article (PubMed ID: 35405781)
41. [Application of Chimeric Antigen Receptor-Modified NK Cells in Multiple Myeloma].
Wei HP; Yang N; Gu ZY; Zhao SS; Wang FY; Luo L; Guan LX; Gao CJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):796-801. PubMed ID: 29950222
[TBL] [Abstract][Full Text] [Related]
42. Constitutive Interleukin-7 Cytokine Signaling Enhances the Persistence of Epstein-Barr Virus-Specific T-Cells.
Sharma S; Sauer T; Omer BA; Shum T; Rollins LA; Rooney CM
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958791
[TBL] [Abstract][Full Text] [Related]
43. Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice.
Hillerdal V; Ramachandran M; Leja J; Essand M
BMC Cancer; 2014 Jan; 14():30. PubMed ID: 24438073
[TBL] [Abstract][Full Text] [Related]
44. [Specific cytotoxicity of a novel HER2-based chimeric antigen receptor modified T lymphocytes against HER2-positive tumor cells].
Tang HJ; Liu YQ; Bian XC; Feng HL; Gu B; Sun H; Zuo CX; Zhou FY; Liu J
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):714-720. PubMed ID: 29050075
[No Abstract] [Full Text] [Related]
45. Development of chimeric antigen receptor-modified T cells for the treatment of esophageal cancer.
Yu F; Wang X; Shi H; Jiang M; Xu J; Sun M; Xu Q; Addai FP; Shi H; Gu J; Zhou Y; Liu L
Tumori; 2021 Aug; 107(4):341-352. PubMed ID: 32988314
[TBL] [Abstract][Full Text] [Related]
46. [The specific cytotoxicities of chimeric antigen receptor-engineered T cells on different lymphomas].
Zhang R; Deng Q; Sui SN; Jin X; Zhao MF
Zhonghua Xue Ye Xue Za Zhi; 2017 Oct; 38(10):842-847. PubMed ID: 29166735
[No Abstract] [Full Text] [Related]
47. [Establishment of human B lymphocyte strain overexpressing Epstein-Barr virus latent membrane protein 1 (LMP1)].
Zhang L; Zhao X; Xin M; Wang L; Wen D; Gao Y; Luo B; Sun M
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2019 Mar; 35(3):206-210. PubMed ID: 31030712
[TBL] [Abstract][Full Text] [Related]
48. [Effects of sodium iodide symporter co-expression on proliferation and cytotoxic activity of chimeric antigen receptor T cells
Tian C; Huang P; He Y; Wang L; Peng Z
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Jul; 42(7):1062-1068. PubMed ID: 35869771
[TBL] [Abstract][Full Text] [Related]
49. T cell engineered with a novel nanobody-based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy.
Hajari Taheri F; Hassani M; Sharifzadeh Z; Behdani M; Arashkia A; Abolhassani M
IUBMB Life; 2019 Sep; 71(9):1259-1267. PubMed ID: 30724452
[TBL] [Abstract][Full Text] [Related]
50. Anti-CD19 CAR T cells potently redirected to kill solid tumor cells.
Ambrose C; Su L; Wu L; Dufort FJ; Sanford T; Birt A; Hackel BJ; Hombach A; Abken H; Lobb RR; Rennert PD
PLoS One; 2021; 16(3):e0247701. PubMed ID: 33735268
[TBL] [Abstract][Full Text] [Related]
51. EBV latency III immortalization program sensitizes B cells to induction of CD95-mediated apoptosis via LMP1: role of NF-kappaB, STAT1, and p53.
Le Clorennec C; Youlyouz-Marfak I; Adriaenssens E; Coll J; Bornkamm GW; Feuillard J
Blood; 2006 Mar; 107(5):2070-8. PubMed ID: 16317104
[TBL] [Abstract][Full Text] [Related]
52. Activity of Anti-CD19 Chimeric Antigen Receptor T Cells Against B Cell Lymphoma Is Enhanced by Antibody-Targeted Interferon-Alpha.
Young PA; Yamada RE; Trinh KR; Vasuthasawat A; De Oliveira S; Yamada DH; Morrison SL; Timmerman JM
J Interferon Cytokine Res; 2018 Jun; 38(6):239-254. PubMed ID: 29920129
[TBL] [Abstract][Full Text] [Related]
53. Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells.
Roex G; Campillo-Davo D; Flumens D; Shaw PAG; Krekelbergh L; De Reu H; Berneman ZN; Lion E; Anguille S
J Transl Med; 2022 Mar; 20(1):124. PubMed ID: 35287669
[TBL] [Abstract][Full Text] [Related]
54. [Establishment of a cytokine release syndrome associated with chimeric antigen receptor T cell treatment in SCID/Beige mice model].
Shan JQ; Nan SF; Li F; Shen CY; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1248-1254. PubMed ID: 34915632
[No Abstract] [Full Text] [Related]
55. CD137 Co-Stimulation Improves The Antitumor Effect Of LMP1-Specific Chimeric Antigen Receptor T Cells In Vitro And In Vivo.
Tang X; Tang Q; Mao Y; Huang X; Jia L; Zhu J; Feng Z
Onco Targets Ther; 2019; 12():9341-9350. PubMed ID: 31807014
[TBL] [Abstract][Full Text] [Related]
56. Bryostatin Activates CAR T-Cell Antigen-Non-Specific Killing (CTAK), and CAR-T NK-Like Killing for Pre-B ALL, While Blocking Cytolysis of a Burkitt Lymphoma Cell Line.
Wang L; Zhang Y; Anderson E; Lamble A; Orentas RJ
Front Immunol; 2022; 13():825364. PubMed ID: 35222407
[TBL] [Abstract][Full Text] [Related]
57. Signaling by the Epstein-Barr virus LMP1 protein induces potent cytotoxic CD4
Choi IK; Wang Z; Ke Q; Hong M; Qian Y; Zhao X; Liu Y; Kim HJ; Ritz J; Cantor H; Rajewsky K; Wucherpfennig KW; Zhang B
Proc Natl Acad Sci U S A; 2018 Jan; 115(4):E686-E695. PubMed ID: 29311309
[TBL] [Abstract][Full Text] [Related]
58. [Effect of Special Structure Bi-Specific Chimeric Antigen Receptor T Cell on Tumor Cells].
Liu C; Peng H; Zeng WJ; Li W; Chen KK; Li WT; Zeng GF; Liang X; Hu JY; Zhou M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1730-1740. PubMed ID: 36476896
[TBL] [Abstract][Full Text] [Related]
59. LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis.
Ma SD; Xu X; Plowshay J; Ranheim EA; Burlingham WJ; Jensen JL; Asimakopoulos F; Tang W; Gulley ML; Cesarman E; Gumperz JE; Kenney SC
J Clin Invest; 2015 Jan; 125(1):304-15. PubMed ID: 25485679
[TBL] [Abstract][Full Text] [Related]
60. 4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2
Dai Q; Han P; Qi X; Li F; Li M; Fan L; Zhang H; Zhang X; Yang X
Front Immunol; 2020; 11():539654. PubMed ID: 33281809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
